IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer

• DOI: 10.1177/0300891618784790
• Publication Date: 2018-07-19T07:14:59Z
• Authors: Hassan Yousefi; Majid Momeny; Seyed H. Ghaffari; Nazanin Parsanejad; Arash Poursheikhani; Sepehr Javadikoos...; Ghazaleh Zarrinrad; Fatemeh Esmaeili; Zivar Alishahi; Zahra Sabourinejad; Ghazaleh Sankanian; Sahar Shamsaiegah...; Davood Bashash; Narjes Shahsavani; Javad Tavakkoly-B...; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
• Keywords: Interleukin-6 receptor; Targeted Therapy; Carboplatin

Introduction: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy worldwide and despite an initial response to therapeutic agents, majority of patients have chemoresistant disease. There no treatment strategy with proven efficacy against EOC in this setting, overcoming therapy resistance key successful treatment. Methods: This study aimed investigate expression interleukin-6 (IL-6) IL-6 receptor (IL-6R) a panel cell lines. To achieve this, its were compared cells using quantitative reverse transcription polymerase chain reaction. MTT assay was performed obtain chemosensitivity cells. Results: In report, we show that expressions IL6 IL6R are higher therapy-resistant sensitive ones. Higher correlated certain chemotherapeutic agents. Moreover, our findings showed combination tocilizumab (Actemra; Roche), anti-IL-6R monoclonal antibody, carboplatin synergistically inhibited growth proliferation direct axis for gene NF-κB pathway. Conclusion: Collectively, suggest blockade signaling pathway anti-IL-6 antibody might resensitize current chemotherapeutics.